India court rules for Cipla against Roche in patent case

MUMBAI, Sept 7 Fri Sep 7, 2012 11:16pm IST

Stocks

   

MUMBAI, Sept 7 (Reuters) - An Indian court has ruled in favour of local drugmaker Cipla in a patent infringement case filed by Switzerland's Roche Holding AG over Cipla's cancer drug Erlocip, a senior executive of the Indian company said.

The Delhi High Court made the ruling a week before India's Supreme Court is due to begin hearing a patent plea by another Swiss drugmaker, Novartis AG, over its cancer drug Glivec. That case is expected to set a precedent for the Indian drug market, where major western companies are fighting to protect their intellectual property.

"The court judgement says we have not infringed any patent," S. Radhakrishnan, a director on Cipla's board, told Reuters late on Friday after the Delhi High Court's ruling.

Roche accuses Cipla of infringing its patent on cancer drug Tarceva, which Cipla sells under the brand name Erlocip.

Roche could not immediately be reached for comment. The company has the option to challenge the judgement in India's Supreme Court.

The ruling comes nearly four years after the court rejected Roche's attempt to stop Cipla from selling Erlocip in India.

The court, however, said that Roche's patent over Tarceva is valid in India, media reports said. (Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and Anthony Barker)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

COAL BLOCK ALLOCATIONS

REUTERS SHOWCASE

Banned From Bidding

Banned From Bidding

India bans Finmeccanica from bidding for contracts amid graft case.  Full Article 

Sugar Talk

Sugar Talk

Sugar export rebound at risk from rising domestic prices.  Full Article 

GDP Preview

GDP Preview

Economy likely grew faster in June quarter: Reuters poll.  Full Article 

New Ordeal

New Ordeal

After disasters, stricken Malaysia Airlines staff brace for job cuts.  Full Article 

Deal Talk

Deal Talk

Kleiner to invest in messaging startup Snapchat at near-$10 bln valuation - report.  Full Article 

Expert Zone

Expert Zone

Column - Why inflation is so persistent.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage